My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Dianthus Therapeutics, Inc. - Common Stock (NQ:DNTH)

41.63 -1.95 (-4.47%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 11, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Dianthus Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >

Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday ↗

March 22, 2024

U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday.

Via Benzinga

Topics Stocks

DNTH Stock Earnings: Dianthus Therapeutics Beats EPS, Beats Revenue for Q4 2023 ↗

March 21, 2024

DNTH stock results show that Dianthus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.

Via InvestorPlace

Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

March 07, 2024

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)

February 26, 2024

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

Decoding 4 Analyst Evaluations For Dianthus Therapeutics ↗

February 15, 2024

Via Benzinga

Why Dianthus Therapeutics (DNTH) Stock Is Exploding Higher ↗

January 22, 2024

Dianthus Therapeutics shares traded higher by 37% Monday. The company announced a $230 million private placement.

Via Benzinga

DNTH Stock Earnings: Dianthus Therapeutics Reported Results for Q3 2023 ↗

December 14, 2023

Dianthus Therapeutics just reported results for the third quarter of 2023.

Via InvestorPlace

Antibody Player Dianthus Therapeutics Has Potential Amid Active M&A Landscape in Complement-Focused Firms: Analyst ↗

November 22, 2023

Wedbush initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), noting its lead program DNTH103 as a well-positioned monoclonal antibody directed against the active form of the

Via Benzinga

Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst ↗

September 28, 2023

Raymond James initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), a recent reverse merger with the old Magenta Therapeutics.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023 ↗

September 28, 2023

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.